DSP 0378
Alternative Names: DSP-0378Latest Information Update: 23 Jan 2023
At a glance
- Originator Sumitomo Pharma
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action GABA A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dravet syndrome; Lennox-Gastaut syndrome
Most Recent Events
- 21 Nov 2022 Phase-I clinical trials in Dravet syndrome (Treatment-resistant, In infants, In children) in Japan (PO) (Sumitomo Pharma pipeline, November 2022)
- 21 Nov 2022 Phase-I clinical trials in Lennox-Gastaut syndrome (Treatment-resistant, In infants, In children) in Japan (PO) (Sumitomo Pharma pipeline, November 2022)